more affinity for either VPS35 or C16orf62; the nature of the stoichiometry of the two complexes in cells; whether VPS19 exchanges from one complex to the other and whether they are co-regulated.
Retromer and retriever have so far primarily been localized to endosomes. However, VPS35 and VPS26 also mediate the transport between mitochondria and peroxisomes 14 , suggesting roles for retromer in the generation of transport intermediates from membranes other than endosomes. It remains to be shown whether retriever could also have such a function and for which membrane compartment. Lastly, mutations in VPS35 and VPS26 have been linked to Parkinson diseases 15 , raising the question of whether mutations in retriever might also lead to neurodegeneration. In summary, McNally et al. have identified a previously unrecognized machinery comprising retriever, a trimeric complex similar to retromer, which together with SNX17, the CCC complex and the WASH complex, mediates endosome-to-plasma-membrane recycling of dozens of plasma membrane receptors (including α 5 β 1 integrins), and opens up many new avenues for future research.
What DKKtates where to metastasize

Wei Zheng and Jeffrey W. Pollard
Cancer cells preferentially metastasize to certain organs. A study in mouse models of breast cancer shows that the DKK1 negative regulator of WNT signalling inhibits tropism to the lung, but enhances tropism to the bone due to the differential regulation of canonical and non-canonical WNT signalling in the two microenvironments.
The process by which cancer cells preferentially metastasize to certain distal organs is known as metastatic organotropism 1 . For example, breast cancer cells tend to home to bone and lung. Organotropism has been recognized for over a century but the exact molecular determinants are unknown, with both cancer cells and environmental influences playing distinct roles. Efforts to profile cancer cells have identified certain genes whose expression is specifically associated with the predisposition to lung and bone metastasis 2, 3 . In addition, tumour education of pre-metastatic niches is caused by a variety of tumour-cell-secreted factors that can result in preferential colonization 4 . It is known that WNT signalling is involved in many aspects of tumorigenesis and metastasis 5 . There are 19 WNT family members in mammals, and they signal through the Frizzled family of receptors that engage in complex interactions with co-receptors that in part mediate cell type specificity. WNTs have three core signalling pathways: a major canonical one that signals through activation of β-catenin transcriptional activity, and two non-canonical ones that operate via Ca 2+ /CaMKII/NF-κB or planar cell polarity (PCP) through RAC1/JNK 5 . Dickkkopf-1 (DKK1) is a soluble antagonist of all of these WNT signalling pathways 6 . In this issue of Nature Cell Biology, Zhuang et al. 7 demonstrate that DKK1 differentially regulates tropism of breast cancer cells to the bone versus the lung.
The authors compared the secretomes of cell lines with different metastatic potentials and organ tropisms, and found that DKK1 was significantly downregulated in cells that tend to metastasize to the lung but significantly upregulated in those favouring bone metastasis. In breast cancer patients, the serum level of DKK1 correlated positively with bone metastasis but inversely with lung metastasis. They thus proposed that DKK1 exerts two opposing metastasis-regulating activities through different signalling pathways, depending on the target organs.
In the lung, using a mildly metastatic cell line, they found that forced expression of DKK1 inhibited lung metastasis, whereas DKK1 knockdown promoted it. These data were confirmed in two other models of breast cancer. As neither DKK1 overexpression nor knockdown altered tumour cell proliferation, apoptosis, migration or spheroid formation in vitro, they reasoned that DKK1 regulated metastasis indirectly through the tumour microenvironment. + /CD11b + neutrophils, both cell types known for their tumourpromoting activities 8 . DKK1 itself did not behave as a chemoattractant for these immune cells, but knockdown of DKK1 in cancer cells resulted in conditioned medium with recruitment activity towards these macrophages and granulocytes, whereas the opposite result was found for DKK1 overexpression. The authors then demonstrated that the recruitment of these leukocytes in vivo was required for the metastasis-promoting activity of reduced DKK1 levels in tumour cells, as this effect was lost following depletion of macrophages and/or neutrophils.
These data suggest that DKK1 acts in an autocrine manner to negatively regulate neutrophil and macrophage migration to the lung, posing the question of the nature of this signalling and the mechanism by which it attracts immune cells. Analysis showed that DKK1 inhibited two branches of the WNT non-canonical pathway in the lung. Inhibition of WNT activity through Rac1/JNK signalling suppressed expression of COX2. As COX2 catalyses production of prostaglandin E2 (PGE2), an immunocyteattracting lipid, its inhibition by DKK1 served as a potential link between tumour-cell-derived and autocrine-acting DKK1 and immune cell infiltration. Indeed, COX2 inhibitors blocked the ability of cancer cells to attract myeloid cells in vitro. In addition, DKK1 inhibition through the second WNT non-canonical pathway, PCP/CaMKII/NF-κB, reduced production of LTBP1 (the latent form of TGF-β1), thus making bioactive TGF-β1 less available for the promotion of lung metastasis (Fig. 1a) .
This mechanism, however, did not apply in bone metastasis. A major reason appeared to be the different nature of the WNT signalling pathways targeted by DKK1 in different cell types in the bone. Whereas DKK1 blocked the pro-metastatic non-canonical WNT pathway in cancer cells in the lung, it inhibited the tumour-suppressive canonical WNT pathway in bone osteoblasts. This inhibition enhanced osteolysis by blocking the production of OPG, an inhibitor of the osteoclast growth factor RANKL. Increased RANKL caused differentiation of osteoclasts, the activity of which released a variety of tumour-promoting factors including TGF-β, in agreement with previous studies conducted in breast and other types of cancer 6 (Fig. 1b) . To verify the dichotomous role of DKK1 in lung and bone metastases in vivo, Zhuang et al. orthotopically grafted breast cancer cells into mouse mammary fat pads and found that DKK1 overexpression suppressed lung metastasis but promoted bone metastasis. This led the authors to suggest that targeting WNT signalling may be efficacious in one organ but deleterious in another.
The secretome of metastasizing cancer cells has become an interesting topic in the past few years, as it represents a form of communication between tumour cells and the tumour microenvironment. Metastasized cancer cells in the lung secrete CCL2, which recruits and regulates the function of inflammatory monocytes and metastasis-associated macrophages -which themselves secrete CCL3 to further amplify the pro-metastatic inflammatory response [9] [10] [11] . As shown in the current work 7 , leukocytic recruitment is also enhanced by PGE2, which recruits both monocytes and neutrophils (Fig. 1a) . Although some of these communications may be general in multiple organs, other types of communication seem to be unique. For example, in the lung but not bone or the brain, stromal cells express BMP, which induces metastasized cancer cells into a quiescent state, thus producing dormant micrometastases. Expression of the soluble BMP antagonist Coco by highly metastatic breast cancer cells in the lung can re-activate the dormant micrometastases 12 (Fig. 1a) . Another study has also shown that DKK1-mediated inhibition of WNT signalling in the lung maintains stem-cell-like dormancy and immune cell avoidance by downregulating ligands for natural killer (NK) cell activation and receptors for death signals 13 ( Fig. 1a) . The exact relationship of these results and those of the current study in proliferating metastatic lesions remains to be determined, but in each case, activation of WNT signalling promoted lung metastasis. These data are also consistent with results from spontaneous mouse models of breast cancer in which myeloid production of WNTs promoted tumour progression and metastasis 14 .
A number of important questions remain. In contrast to its uniform expression in established cancer cell lines, does DKK1 exhibit heterogeneous expression in spontaneously developed tumours, with the high-expressing cells colonizing bone and the low-expressing cells colonizing the lung? Does DKK1 determine only In bone, inhibition of canonical WNT signalling by DKK1 results in the inhibition of OPG expression through the canonical pathway that in turn blocks the action of RANKL, which promotes osteoclast formation. The resultant RANKL induction of osteoclast formation increases osteolysis, liberating a rich reservoir of growth factors (GFs), including TGF-β. These effects enhance metastasis. Given these contrasting data in lung and bone, Zhuang et al. 7 showed that only combined targeting of TGF-β and JNK (red lightning symbols) effectively inhibited both lung and bone metastasis. whether disseminated cancer cells colonize a certain site, without influencing the selection of cells that are able to disseminate from the primary site? There is also evidence for the role of WNT signalling in the formation of pre-metastatic niches that direct and nurture metastasizing tumour cells, and it would be interesting to know how this aspect fits into the picture 4 . A major challenge in these studies is the complexity of WNT signalling, which involves a large number of ligands (both agonists and antagonists) and receptors/co-receptors. Clarifying this signalling may explain why DKK1 blocks non-canonical pathways in the lung and the canonical pathway in the bone. Thus, although
Zhuang et al. and other studies have shown that WNT signalling has roles in many aspects of the metastatic cascade, there is still much more to understand about signalling at individual steps and in different organs. Nevertheless, the study by Zhuang et al. is an excellent example that metastasis should be considered as a systemic disease, and that understanding the molecular mechanisms within the local tumour microenvironment, in addition to the phenotypic characterization of cancer cells, represents the key to rational therapeutic designs. Consistent with this view, combinatorial inhibition of JNK and TGF-β effectively suppressed both lung and bone metastasis (Fig. 1) .
